NCT04992195Completed
Impact of COVID-19 Vaccines on Cerebrovascular Health
Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future. On the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise "young-and-fit" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health. In this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 415 (actual)
- First submitted
- 3 Aug 2021
- Start date
- 5 Jul 2021
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Stroke, Alzheimer disease
- NCT number
- NCT04992195
What you commit to
- Study type: Observational
- Participants enrolled: 415
- From 5 Jul 2021 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Citizens with clinically evident stroke or dementia prior to recruitment; or
- Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or
Other
- Citizens who are unable to provide an informed consent; or
- Citizens who had no baseline MRI brain assessment.
Who the study is looking for
- All consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.